APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vaginitis Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Vaginitis Drug Industry Research Report 2026

20 December 2025143 pages

Choose your research edition.

Industry ResearchVaginitis Drug Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaginitis Drug Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Vaginitis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaginitis Drug Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaginitis Drug Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Vaginitis Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Vaginitis Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Vaginitis Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Vaginitis Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Vaginitis Drug include Bausch Health, Dare Bioscience, Galderma, Globela Pharma, Lupin Pharmaceuticals, Padagis, Perrigo, Prestige Consumer Healthcare and Sandoz, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Vaginitis Drug market in terms of revenue (US$ million) and, where applicable, service volume (Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Vaginitis Drug.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Vaginitis Drug Market by Company

Bausch Health

Dare Bioscience

Galderma

Globela Pharma

Lupin Pharmaceuticals

Padagis

Perrigo

Prestige Consumer Healthcare

Sandoz

Bayer

Sinopharm Group

HCPC

CR-Double Crane Pharmaceuticals

Pfizer

Conba

Kelun Pharmaceuticals

Livzon Pharmaceuticals

Lukang Pharmaceuticals

Luoxin Pharmaceuticals

Johnson & Johnson

Sanofi

Shandong Shijiazhuang Pharmaceutical Group

Teva Pharmaceuticals

Tongfang Pharmaceuticals

Wuhan Haite Biopharmaceuticals

Yuanda Pharmaceuticals

Yunnan Baiyao

Vaginitis Drug Segment by Type

External Drug

Oral Drug

Vaginitis Drug Segment by Application

Hospital Phamacy

Retail Phamacy

Online

Vaginitis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaginitis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaginitis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaginitis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Vaginitis Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Vaginitis Drug Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Vaginitis Drug Revenue Market Share by Type (2021-2026) Table 7. Global Vaginitis Drug Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Vaginitis Drug Revenue Market Share by Type (2027-2032) Table 9. Global Vaginitis Drug Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Vaginitis Drug Revenue Market Share by Application (2021-2026) Table 11. Global Vaginitis Drug Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Vaginitis Drug Revenue Market Share by Application (2027-2032) Table 13. Global Vaginitis Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Vaginitis Drug Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Vaginitis Drug Market Share by Region (2021-2026) Table 16. Global Vaginitis Drug Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Vaginitis Drug Market Share by Region (2027-2032) Table 18. Vaginitis Drug Industry Trends Table 19. Vaginitis Drug Industry Drivers Table 20. Vaginitis Drug Industry Opportunities and Challenges Table 21. Vaginitis Drug Market Restraints Table 22. Global Top Vaginitis Drug Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Vaginitis Drug Revenue Market Share by Players (2021-2026) Table 24. Global Vaginitis Drug Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Vaginitis Drug, Headquarters and Area Served Table 26. Global Vaginitis Drug Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Vaginitis Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Vaginitis Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Vaginitis Drug Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Vaginitis Drug Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Vaginitis Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Vaginitis Drug Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Vaginitis Drug Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Vaginitis Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Vaginitis Drug Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Vaginitis Drug Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Vaginitis Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Vaginitis Drug Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Vaginitis Drug Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Vaginitis Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Vaginitis Drug Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Vaginitis Drug Market Size by Country (2027-2032) & (US$ Million) Table 45. Bausch Health Company Information Table 46. Bausch Health Business Overview Table 47. Bausch Health Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 48. Bausch Health Vaginitis Drug Product Portfolio Table 49. Bausch Health Recent Developments Table 50. Dare Bioscience Company Information Table 51. Dare Bioscience Business Overview Table 52. Dare Bioscience Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 53. Dare Bioscience Vaginitis Drug Product Portfolio Table 54. Dare Bioscience Recent Developments Table 55. Galderma Company Information Table 56. Galderma Business Overview Table 57. Galderma Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 58. Galderma Vaginitis Drug Product Portfolio Table 59. Galderma Recent Developments Table 60. Globela Pharma Company Information Table 61. Globela Pharma Business Overview Table 62. Globela Pharma Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 63. Globela Pharma Vaginitis Drug Product Portfolio Table 64. Globela Pharma Recent Developments Table 65. Lupin Pharmaceuticals Company Information Table 66. Lupin Pharmaceuticals Business Overview Table 67. Lupin Pharmaceuticals Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 68. Lupin Pharmaceuticals Vaginitis Drug Product Portfolio Table 69. Lupin Pharmaceuticals Recent Developments Table 70. Padagis Company Information Table 71. Padagis Business Overview Table 72. Padagis Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 73. Padagis Vaginitis Drug Product Portfolio Table 74. Padagis Recent Developments Table 75. Perrigo Company Information Table 76. Perrigo Business Overview Table 77. Perrigo Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 78. Perrigo Vaginitis Drug Product Portfolio Table 79. Perrigo Recent Developments Table 80. Prestige Consumer Healthcare Company Information Table 81. Prestige Consumer Healthcare Business Overview Table 82. Prestige Consumer Healthcare Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 83. Prestige Consumer Healthcare Vaginitis Drug Product Portfolio Table 84. Prestige Consumer Healthcare Recent Developments Table 85. Sandoz Company Information Table 86. Sandoz Business Overview Table 87. Sandoz Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 88. Sandoz Vaginitis Drug Product Portfolio Table 89. Sandoz Recent Developments Table 90. Bayer Company Information Table 91. Bayer Business Overview Table 92. Bayer Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 93. Bayer Vaginitis Drug Product Portfolio Table 94. Bayer Recent Developments Table 95. Sinopharm Group Company Information Table 96. Sinopharm Group Business Overview Table 97. Sinopharm Group Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 98. Sinopharm Group Vaginitis Drug Product Portfolio Table 99. Sinopharm Group Recent Developments Table 100. HCPC Company Information Table 101. HCPC Business Overview Table 102. HCPC Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 103. HCPC Vaginitis Drug Product Portfolio Table 104. HCPC Recent Developments Table 105. CR-Double Crane Pharmaceuticals Company Information Table 106. CR-Double Crane Pharmaceuticals Business Overview Table 107. CR-Double Crane Pharmaceuticals Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 108. CR-Double Crane Pharmaceuticals Vaginitis Drug Product Portfolio Table 109. CR-Double Crane Pharmaceuticals Recent Developments Table 110. Pfizer Company Information Table 111. Pfizer Business Overview Table 112. Pfizer Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 113. Pfizer Vaginitis Drug Product Portfolio Table 114. Pfizer Recent Developments Table 115. Conba Company Information Table 116. Conba Business Overview Table 117. Conba Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 118. Conba Vaginitis Drug Product Portfolio Table 119. Conba Recent Developments Table 120. Kelun Pharmaceuticals Company Information Table 121. Kelun Pharmaceuticals Business Overview Table 122. Kelun Pharmaceuticals Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 123. Kelun Pharmaceuticals Vaginitis Drug Product Portfolio Table 124. Kelun Pharmaceuticals Recent Developments Table 125. Livzon Pharmaceuticals Company Information Table 126. Livzon Pharmaceuticals Business Overview Table 127. Livzon Pharmaceuticals Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 128. Livzon Pharmaceuticals Vaginitis Drug Product Portfolio Table 129. Livzon Pharmaceuticals Recent Developments Table 130. Lukang Pharmaceuticals Company Information Table 131. Lukang Pharmaceuticals Business Overview Table 132. Lukang Pharmaceuticals Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 133. Lukang Pharmaceuticals Vaginitis Drug Product Portfolio Table 134. Lukang Pharmaceuticals Recent Developments Table 135. Luoxin Pharmaceuticals Company Information Table 136. Luoxin Pharmaceuticals Business Overview Table 137. Luoxin Pharmaceuticals Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 138. Luoxin Pharmaceuticals Vaginitis Drug Product Portfolio Table 139. Luoxin Pharmaceuticals Recent Developments Table 140. Johnson & Johnson Company Information Table 141. Johnson & Johnson Business Overview Table 142. Johnson & Johnson Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 143. Johnson & Johnson Vaginitis Drug Product Portfolio Table 144. Johnson & Johnson Recent Developments Table 145. Sanofi Company Information Table 146. Sanofi Business Overview Table 147. Sanofi Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 148. Sanofi Vaginitis Drug Product Portfolio Table 149. Sanofi Recent Developments Table 150. Shandong Shijiazhuang Pharmaceutical Group Company Information Table 151. Shandong Shijiazhuang Pharmaceutical Group Business Overview Table 152. Shandong Shijiazhuang Pharmaceutical Group Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 153. Shandong Shijiazhuang Pharmaceutical Group Vaginitis Drug Product Portfolio Table 154. Shandong Shijiazhuang Pharmaceutical Group Recent Developments Table 155. Teva Pharmaceuticals Company Information Table 156. Teva Pharmaceuticals Business Overview Table 157. Teva Pharmaceuticals Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 158. Teva Pharmaceuticals Vaginitis Drug Product Portfolio Table 159. Teva Pharmaceuticals Recent Developments Table 160. Tongfang Pharmaceuticals Company Information Table 161. Tongfang Pharmaceuticals Business Overview Table 162. Tongfang Pharmaceuticals Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 163. Tongfang Pharmaceuticals Vaginitis Drug Product Portfolio Table 164. Tongfang Pharmaceuticals Recent Developments Table 165. Wuhan Haite Biopharmaceuticals Company Information Table 166. Wuhan Haite Biopharmaceuticals Business Overview Table 167. Wuhan Haite Biopharmaceuticals Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 168. Wuhan Haite Biopharmaceuticals Vaginitis Drug Product Portfolio Table 169. Wuhan Haite Biopharmaceuticals Recent Developments Table 170. Yuanda Pharmaceuticals Company Information Table 171. Yuanda Pharmaceuticals Business Overview Table 172. Yuanda Pharmaceuticals Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 173. Yuanda Pharmaceuticals Vaginitis Drug Product Portfolio Table 174. Yuanda Pharmaceuticals Recent Developments Table 175. Yunnan Baiyao Company Information Table 176. Yunnan Baiyao Business Overview Table 177. Yunnan Baiyao Revenue in Vaginitis Drug Business (2021-2026) & (US$ Million) Table 178. Yunnan Baiyao Vaginitis Drug Product Portfolio Table 179. Yunnan Baiyao Recent Developments Table 180. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Vaginitis Drug Product Image Figure 5. Global Vaginitis Drug Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Vaginitis Drug Market Share by Type: 2025 VS 2032 Figure 7. External Drug Product Figure 8. Oral Drug Product Figure 9. Global Vaginitis Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Vaginitis Drug Market Share by Application: 2025 VS 2032 Figure 11. Hospital Phamacy Product Figure 12. Retail Phamacy Product Figure 13. Online Product Figure 14. Global Vaginitis Drug Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 15. Global Vaginitis Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Vaginitis Drug Market Share by Region: 2025 VS 2032 Figure 17. Global Vaginitis Drug Market Share by Players in 2025 Figure 18. Global Vaginitis Drug Manufacturers Established Date Figure 19. Global Top 5 and 10 Vaginitis Drug Players Market Share by Revenue in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. North America Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Vaginitis Drug Market Share by Country (2021-2032) Figure 23. United States Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Canada Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Mexico Vaginitis Drug Market Share by Country (2021-2032) Figure 26. Europe Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Europe Vaginitis Drug Market Share by Country (2021-2032) Figure 28. Germany Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. France Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. U.K. Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Italy Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Spain Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Russia Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Netherlands Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Nordic Countries Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Vaginitis Drug Market Share by Country (2021-2032) Figure 38. China Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Japan Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. South Korea Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. India Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. India Vaginitis Drug Market Share by Country (2021-2032) Figure 43. Australia Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. China Taiwan Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. Southeast Asia Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. South America Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. South America Vaginitis Drug Market Share by Country (2021-2032) Figure 48. Brazil Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. Argentina Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Chile Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Colombia Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Peru Vaginitis Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Bausch Health Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 54. Dare Bioscience Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 55. Galderma Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 56. Globela Pharma Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 57. Lupin Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 58. Padagis Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 59. Perrigo Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 60. Prestige Consumer Healthcare Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 61. Sandoz Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 62. Bayer Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 63. Sinopharm Group Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 64. HCPC Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 65. CR-Double Crane Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 66. Pfizer Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 67. Conba Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 68. Kelun Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 69. Livzon Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 70. Lukang Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 71. Luoxin Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 72. Johnson & Johnson Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 73. Sanofi Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 74. Shandong Shijiazhuang Pharmaceutical Group Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 75. Teva Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 76. Tongfang Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 77. Wuhan Haite Biopharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 78. Yuanda Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2021-2026) Figure 79. Yunnan Baiyao Revenue Growth Rate in Vaginitis Drug Business (2021-2026)

Scope & coverage.

Types
  • External Drug
  • Oral Drug
Applications
  • Hospital Phamacy
  • Retail Phamacy
  • Online
Companies covered
  • Bausch Health
  • Dare Bioscience
  • Galderma
  • Globela Pharma
  • Lupin Pharmaceuticals
  • Padagis
  • Perrigo
  • Prestige Consumer Healthcare
  • Sandoz
  • Bayer
  • Sinopharm Group
  • HCPC
  • CR-Double Crane Pharmaceuticals
  • Pfizer
  • Conba
  • Kelun Pharmaceuticals
  • Livzon Pharmaceuticals
  • Lukang Pharmaceuticals
  • Luoxin Pharmaceuticals
  • Johnson & Johnson
  • Sanofi
  • Shandong Shijiazhuang Pharmaceutical Group
  • Teva Pharmaceuticals
  • Tongfang Pharmaceuticals
  • Wuhan Haite Biopharmaceuticals
  • Yuanda Pharmaceuticals
  • Yunnan Baiyao

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Vaginitis Drug by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 External Drug
  5. 2.2.3 Oral Drug
  6. 2.3 Vaginitis Drug by Application
  7. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  8. 2.3.2 Hospital Phamacy
  9. 2.3.3 Retail Phamacy
  10. 2.3.4 Online
  11. 2.4 Assumptions and Limitations
3 Vaginitis Drug Breakdown Data by Type
  1. 3.1 Global Vaginitis Drug Historic Market Size by Type (2021-2026)
  2. 3.2 Global Vaginitis Drug Forecasted Market Size by Type (2027-2032)
4 Vaginitis Drug Breakdown Data by Application
  1. 4.1 Global Vaginitis Drug Historic Market Size by Application (2021-2026)
  2. 4.2 Global Vaginitis Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Vaginitis Drug Market Perspective (2021-2032)
  2. 5.2 Global Vaginitis Drug Growth Trends by Region
  3. 5.2.1 Global Vaginitis Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Vaginitis Drug Historic Market Size by Region (2021-2026)
  5. 5.2.3 Vaginitis Drug Forecasted Market Size by Region (2027-2032)
  6. 5.3 Vaginitis Drug Market Dynamics
  7. 5.3.1 Vaginitis Drug Industry Trends
  8. 5.3.2 Vaginitis Drug Market Drivers
  9. 5.3.3 Vaginitis Drug Market Challenges
  10. 5.3.4 Vaginitis Drug Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Vaginitis Drug Players by Revenue
  2. 6.1.1 Global Top Vaginitis Drug Players by Revenue (2021-2026)
  3. 6.1.2 Global Vaginitis Drug Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Vaginitis Drug Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Vaginitis Drug Head Office and Area Served
  6. 6.4 Global Vaginitis Drug Players, Product Type & Application
  7. 6.5 Global Vaginitis Drug Manufacturers Established Date
  8. 6.6 Global Vaginitis Drug Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Vaginitis Drug Market Size (2021-2032)
  2. 7.2 North America Vaginitis Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Vaginitis Drug Market Size by Country (2021-2026)
  4. 7.4 North America Vaginitis Drug Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Vaginitis Drug Market Size (2021-2032)
  2. 8.2 Europe Vaginitis Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Vaginitis Drug Market Size by Country (2021-2026)
  4. 8.4 Europe Vaginitis Drug Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Vaginitis Drug Market Size (2021-2032)
  2. 9.2 Asia-Pacific Vaginitis Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Vaginitis Drug Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Vaginitis Drug Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Vaginitis Drug Market Size (2021-2032)
  2. 10.2 South America Vaginitis Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Vaginitis Drug Market Size by Country (2021-2026)
  4. 10.4 South America Vaginitis Drug Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Vaginitis Drug Market Size (2021-2032)
  2. 11.2 Middle East & Africa Vaginitis Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Vaginitis Drug Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Vaginitis Drug Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Bausch Health
  2. 12.1.1 Bausch Health Company Information
  3. 12.1.2 Bausch Health Business Overview
  4. 12.1.3 Bausch Health Revenue in Vaginitis Drug Business (2021-2026)
  5. 12.1.4 Bausch Health Vaginitis Drug Product Portfolio
  6. 12.1.5 Bausch Health Recent Developments
  7. 12.2 Dare Bioscience
  8. 12.2.1 Dare Bioscience Company Information
  9. 12.2.2 Dare Bioscience Business Overview
  10. 12.2.3 Dare Bioscience Revenue in Vaginitis Drug Business (2021-2026)
  11. 12.2.4 Dare Bioscience Vaginitis Drug Product Portfolio
  12. 12.2.5 Dare Bioscience Recent Developments
  13. 12.3 Galderma
  14. 12.3.1 Galderma Company Information
  15. 12.3.2 Galderma Business Overview
  16. 12.3.3 Galderma Revenue in Vaginitis Drug Business (2021-2026)
  17. 12.3.4 Galderma Vaginitis Drug Product Portfolio
  18. 12.3.5 Galderma Recent Developments
  19. 12.4 Globela Pharma
  20. 12.4.1 Globela Pharma Company Information
  21. 12.4.2 Globela Pharma Business Overview
  22. 12.4.3 Globela Pharma Revenue in Vaginitis Drug Business (2021-2026)
  23. 12.4.4 Globela Pharma Vaginitis Drug Product Portfolio
  24. 12.4.5 Globela Pharma Recent Developments
  25. 12.5 Lupin Pharmaceuticals
  26. 12.5.1 Lupin Pharmaceuticals Company Information
  27. 12.5.2 Lupin Pharmaceuticals Business Overview
  28. 12.5.3 Lupin Pharmaceuticals Revenue in Vaginitis Drug Business (2021-2026)
  29. 12.5.4 Lupin Pharmaceuticals Vaginitis Drug Product Portfolio
  30. 12.5.5 Lupin Pharmaceuticals Recent Developments
  31. 12.6 Padagis
  32. 12.6.1 Padagis Company Information
  33. 12.6.2 Padagis Business Overview
  34. 12.6.3 Padagis Revenue in Vaginitis Drug Business (2021-2026)
  35. 12.6.4 Padagis Vaginitis Drug Product Portfolio
  36. 12.6.5 Padagis Recent Developments
  37. 12.7 Perrigo
  38. 12.7.1 Perrigo Company Information
  39. 12.7.2 Perrigo Business Overview
  40. 12.7.3 Perrigo Revenue in Vaginitis Drug Business (2021-2026)
  41. 12.7.4 Perrigo Vaginitis Drug Product Portfolio
  42. 12.7.5 Perrigo Recent Developments
  43. 12.8 Prestige Consumer Healthcare
  44. 12.8.1 Prestige Consumer Healthcare Company Information
  45. 12.8.2 Prestige Consumer Healthcare Business Overview
  46. 12.8.3 Prestige Consumer Healthcare Revenue in Vaginitis Drug Business (2021-2026)
  47. 12.8.4 Prestige Consumer Healthcare Vaginitis Drug Product Portfolio
  48. 12.8.5 Prestige Consumer Healthcare Recent Developments
  49. 12.9 Sandoz
  50. 12.9.1 Sandoz Company Information
  51. 12.9.2 Sandoz Business Overview
  52. 12.9.3 Sandoz Revenue in Vaginitis Drug Business (2021-2026)
  53. 12.9.4 Sandoz Vaginitis Drug Product Portfolio
  54. 12.9.5 Sandoz Recent Developments
  55. 12.10 Bayer
  56. 12.10.1 Bayer Company Information
  57. 12.10.2 Bayer Business Overview
  58. 12.10.3 Bayer Revenue in Vaginitis Drug Business (2021-2026)
  59. 12.10.4 Bayer Vaginitis Drug Product Portfolio
  60. 12.10.5 Bayer Recent Developments
  61. 12.11 Sinopharm Group
  62. 12.11.1 Sinopharm Group Company Information
  63. 12.11.2 Sinopharm Group Business Overview
  64. 12.11.3 Sinopharm Group Revenue in Vaginitis Drug Business (2021-2026)
  65. 12.11.4 Sinopharm Group Vaginitis Drug Product Portfolio
  66. 12.11.5 Sinopharm Group Recent Developments
  67. 12.12 HCPC
  68. 12.12.1 HCPC Company Information
  69. 12.12.2 HCPC Business Overview
  70. 12.12.3 HCPC Revenue in Vaginitis Drug Business (2021-2026)
  71. 12.12.4 HCPC Vaginitis Drug Product Portfolio
  72. 12.12.5 HCPC Recent Developments
  73. 12.13 CR-Double Crane Pharmaceuticals
  74. 12.13.1 CR-Double Crane Pharmaceuticals Company Information
  75. 12.13.2 CR-Double Crane Pharmaceuticals Business Overview
  76. 12.13.3 CR-Double Crane Pharmaceuticals Revenue in Vaginitis Drug Business (2021-2026)
  77. 12.13.4 CR-Double Crane Pharmaceuticals Vaginitis Drug Product Portfolio
  78. 12.13.5 CR-Double Crane Pharmaceuticals Recent Developments
  79. 12.14 Pfizer
  80. 12.14.1 Pfizer Company Information
  81. 12.14.2 Pfizer Business Overview
  82. 12.14.3 Pfizer Revenue in Vaginitis Drug Business (2021-2026)
  83. 12.14.4 Pfizer Vaginitis Drug Product Portfolio
  84. 12.14.5 Pfizer Recent Developments
  85. 12.15 Conba
  86. 12.15.1 Conba Company Information
  87. 12.15.2 Conba Business Overview
  88. 12.15.3 Conba Revenue in Vaginitis Drug Business (2021-2026)
  89. 12.15.4 Conba Vaginitis Drug Product Portfolio
  90. 12.15.5 Conba Recent Developments
  91. 12.16 Kelun Pharmaceuticals
  92. 12.16.1 Kelun Pharmaceuticals Company Information
  93. 12.16.2 Kelun Pharmaceuticals Business Overview
  94. 12.16.3 Kelun Pharmaceuticals Revenue in Vaginitis Drug Business (2021-2026)
  95. 12.16.4 Kelun Pharmaceuticals Vaginitis Drug Product Portfolio
  96. 12.16.5 Kelun Pharmaceuticals Recent Developments
  97. 12.17 Livzon Pharmaceuticals
  98. 12.17.1 Livzon Pharmaceuticals Company Information
  99. 12.17.2 Livzon Pharmaceuticals Business Overview
  100. 12.17.3 Livzon Pharmaceuticals Revenue in Vaginitis Drug Business (2021-2026)
  101. 12.17.4 Livzon Pharmaceuticals Vaginitis Drug Product Portfolio
  102. 12.17.5 Livzon Pharmaceuticals Recent Developments
  103. 12.18 Lukang Pharmaceuticals
  104. 12.18.1 Lukang Pharmaceuticals Company Information
  105. 12.18.2 Lukang Pharmaceuticals Business Overview
  106. 12.18.3 Lukang Pharmaceuticals Revenue in Vaginitis Drug Business (2021-2026)
  107. 12.18.4 Lukang Pharmaceuticals Vaginitis Drug Product Portfolio
  108. 12.18.5 Lukang Pharmaceuticals Recent Developments
  109. 12.19 Luoxin Pharmaceuticals
  110. 12.19.1 Luoxin Pharmaceuticals Company Information
  111. 12.19.2 Luoxin Pharmaceuticals Business Overview
  112. 12.19.3 Luoxin Pharmaceuticals Revenue in Vaginitis Drug Business (2021-2026)
  113. 12.19.4 Luoxin Pharmaceuticals Vaginitis Drug Product Portfolio
  114. 12.19.5 Luoxin Pharmaceuticals Recent Developments
  115. 12.20 Johnson & Johnson
  116. 12.20.1 Johnson & Johnson Company Information
  117. 12.20.2 Johnson & Johnson Business Overview
  118. 12.20.3 Johnson & Johnson Revenue in Vaginitis Drug Business (2021-2026)
  119. 12.20.4 Johnson & Johnson Vaginitis Drug Product Portfolio
  120. 12.20.5 Johnson & Johnson Recent Developments
  121. 12.21 Sanofi
  122. 12.21.1 Sanofi Company Information
  123. 12.21.2 Sanofi Business Overview
  124. 12.21.3 Sanofi Revenue in Vaginitis Drug Business (2021-2026)
  125. 12.21.4 Sanofi Vaginitis Drug Product Portfolio
  126. 12.21.5 Sanofi Recent Developments
  127. 12.22 Shandong Shijiazhuang Pharmaceutical Group
  128. 12.22.1 Shandong Shijiazhuang Pharmaceutical Group Company Information
  129. 12.22.2 Shandong Shijiazhuang Pharmaceutical Group Business Overview
  130. 12.22.3 Shandong Shijiazhuang Pharmaceutical Group Revenue in Vaginitis Drug Business (2021-2026)
  131. 12.22.4 Shandong Shijiazhuang Pharmaceutical Group Vaginitis Drug Product Portfolio
  132. 12.22.5 Shandong Shijiazhuang Pharmaceutical Group Recent Developments
  133. 12.23 Teva Pharmaceuticals
  134. 12.23.1 Teva Pharmaceuticals Company Information
  135. 12.23.2 Teva Pharmaceuticals Business Overview
  136. 12.23.3 Teva Pharmaceuticals Revenue in Vaginitis Drug Business (2021-2026)
  137. 12.23.4 Teva Pharmaceuticals Vaginitis Drug Product Portfolio
  138. 12.23.5 Teva Pharmaceuticals Recent Developments
  139. 12.24 Tongfang Pharmaceuticals
  140. 12.24.1 Tongfang Pharmaceuticals Company Information
  141. 12.24.2 Tongfang Pharmaceuticals Business Overview
  142. 12.24.3 Tongfang Pharmaceuticals Revenue in Vaginitis Drug Business (2021-2026)
  143. 12.24.4 Tongfang Pharmaceuticals Vaginitis Drug Product Portfolio
  144. 12.24.5 Tongfang Pharmaceuticals Recent Developments
  145. 12.25 Wuhan Haite Biopharmaceuticals
  146. 12.25.1 Wuhan Haite Biopharmaceuticals Company Information
  147. 12.25.2 Wuhan Haite Biopharmaceuticals Business Overview
  148. 12.25.3 Wuhan Haite Biopharmaceuticals Revenue in Vaginitis Drug Business (2021-2026)
  149. 12.25.4 Wuhan Haite Biopharmaceuticals Vaginitis Drug Product Portfolio
  150. 12.25.5 Wuhan Haite Biopharmaceuticals Recent Developments
  151. 12.26 Yuanda Pharmaceuticals
  152. 12.26.1 Yuanda Pharmaceuticals Company Information
  153. 12.26.2 Yuanda Pharmaceuticals Business Overview
  154. 12.26.3 Yuanda Pharmaceuticals Revenue in Vaginitis Drug Business (2021-2026)
  155. 12.26.4 Yuanda Pharmaceuticals Vaginitis Drug Product Portfolio
  156. 12.26.5 Yuanda Pharmaceuticals Recent Developments
  157. 12.27 Yunnan Baiyao
  158. 12.27.1 Yunnan Baiyao Company Information
  159. 12.27.2 Yunnan Baiyao Business Overview
  160. 12.27.3 Yunnan Baiyao Revenue in Vaginitis Drug Business (2021-2026)
  161. 12.27.4 Yunnan Baiyao Vaginitis Drug Product Portfolio
  162. 12.27.5 Yunnan Baiyao Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst